NASDAQ:MRKRTapImmune Stock Price, Forecast & News

$2.23

-0.24 (-9.72 %)

(As of 05/29/2020 03:24 PM ET)

Add

Compare

Today's Range

$2.19

Now: $2.23▼

$2.56

50-Day Range

$1.69

MA: $2.25▼

$2.79

52-Week Range

$1.33

Now: $2.23▼

$9.17

Volume723,722 shs

Average Volume771,139 shs

Market Capitalization$103.76 million

P/E RatioN/A

Dividend YieldN/A

Beta0.64

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
TapImmune has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.08, TapImmune has a potential upside of 303.7% from its current price of $2.25.
Amount of Analyst Coverage
TapImmune has only been the subject of 2 research reports in the past 90 days.

2.4 Community Rank

Outperform Votes
TapImmune has received 57 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TapImmune has received 64 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TapImmune has received 52.89% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TapImmune and other stocks. Vote “Outperform” if you believe MRKR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MRKR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TapImmune does not currently pay a dividend.
Dividend Growth
TapImmune does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TapImmune insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 30.90% of the stock of TapImmune is held by insiders.
Percentage Held by Institutions
Only 32.07% of the stock of TapImmune is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for TapImmune are expected to decrease in the coming year, from ($0.58) to ($0.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of TapImmune is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TapImmune is -4.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TapImmune has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.16 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MRKR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.markertherapeutics.com

Phone713-400-6400

Debt

Debt-to-Equity Ratio0.01

Current Ratio13.27

Quick Ratio13.27

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$210,000.00

Price / Sales494.10

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.85 per share

Price / Book2.62

Profitability

EPS (Most Recent Fiscal Year)($0.47)

Net Income$-21,430,000.00

Net MarginsN/A

Return on Equity-49.42%

Return on Assets-46.19%

Miscellaneous

Employees11

Outstanding Shares46,530,000

Market Cap$103.76 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

TapImmune (NASDAQ:MRKR) Frequently Asked Questions

How has TapImmune's stock been impacted by COVID-19 (Coronavirus)?

TapImmune's stock was trading at $1.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRKR shares have increased by 13.6% and is now trading at $2.25. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TapImmune?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TapImmune in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TapImmune.

When is TapImmune's next earnings date?

TapImmune is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for TapImmune.

How were TapImmune's earnings last quarter?

TapImmune Inc. (NASDAQ:MRKR) announced its quarterly earnings data on Monday, May, 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.03. View TapImmune's earnings history.

What price target have analysts set for MRKR?

6 analysts have issued 12 month target prices for TapImmune's stock. Their forecasts range from $2.50 to $16.00. On average, they expect TapImmune's share price to reach $9.08 in the next twelve months. This suggests a possible upside of 303.7% from the stock's current price. View analysts' price targets for TapImmune.

Has TapImmune been receiving favorable news coverage?

News coverage about MRKR stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. TapImmune earned a news impact score of -1.6 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutTapImmune.

Who are some of TapImmune's key competitors?

Some companies that are related to TapImmune include VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Flexion Therapeutics (FLXN), BioSpecifics Technologies (BSTC), Fulcrum Therapeutics (FULC), Syros Pharmaceuticals (SYRS), Catalyst Pharmaceuticals (CPRX), RAPT Therapeutics (RAPT), Satsuma Pharmaceuticals (STSA), Mirum Pharmaceuticals (MIRM), Puma Biotechnology (PBYI), Calithera Biosciences (CALA), CytomX Therapeutics (CTMX), Merus (MRUS) and Albireo Pharma (ALBO). View all competitors.

What other stocks do shareholders of TapImmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TapImmune investors own include SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Alibaba Group (BABA), Flexion Therapeutics (FLXN), Outlook Therapeutics (OTLK), AzurRx BioPharma (AZRX), Genocea Biosciences (GNCA) and InVitae (NVTA).

Who are TapImmune's key executives?

TapImmune's management team includes the following people:

Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 47)
Mr. Anthony H. Kim, Chief Financial Officer (Age 43)
Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 53)
Dr. Ann M. Leen, Chief Scientific Officer
Ms. Elizabeth Donnelly, Director of Admin.

What is TapImmune's stock symbol?

TapImmune trades on the NASDAQ under the ticker symbol "MRKR."

How do I buy shares of TapImmune?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TapImmune's stock price today?

One share of MRKR stock can currently be purchased for approximately $2.25.

How big of a company is TapImmune?

TapImmune has a market capitalization of $104.69 million and generates $210,000.00 in revenue each year. The company earns $-21,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. TapImmune employs 11 workers across the globe.

What is TapImmune's official website?

The official website for TapImmune is www.markertherapeutics.com.

How can I contact TapImmune?

TapImmune's mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff